Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Mylan NV (NASDAQ:MYL)

46.73
Delayed Data
As of Jan 19
 0.00 / 0.00%
Today’s Change
29.39
Today|||52-Week Range
47.25
+10.45%
Year-to-Date
Why Hospitals Shouldn't Terrify Generic Drug Companies
Jan 18 / TheStreet.com - Paid Partner Content
Allergan's (AGN) Sales Guidance for 2018 Lower Than Expected
Jan 09 / Zacks.com - Paid Partner Content
Generic-Drug Stocks Are Looking Sickly
Jan 18 / TheStreet.com - Paid Partner Content
Momenta Reports Positive Top-Line Data on Antibody M281
Jan 09 / Zacks.com - Paid Partner Content
Teva's Trisenox Gets FDA Approval as First-Line Treatment
Jan 16 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close46.73
Today’s open46.59
Day’s range45.05 - 46.96
Volume7,894,686
Average volume (3 months)6,348,674
Market cap$25.1B
Data as of 4:00pm ET, 01/19/2018

Growth & Valuation

Earnings growth (last year)-45.88%
Earnings growth (this year)-7.14%
Earnings growth (next 5 years)+4.00%
Revenue growth (last year)+17.44%
P/E ratio28.5
Price/Sales1.79
Price/Book2.25

Competitors

 Today’s
change
Today’s
% change
BMRNBiomarin Pharmaceuti...0.000.00%
PRGOPerrigo Company PLC0.000.00%
JAZZJazz Pharmaceuticals...0.000.00%
ALNYAlnylam Pharmaceutic...0.000.00%
Data as of 4:02pm ET, 01/19/2018

Financials

Next reporting dateFebruary 28, 2018
EPS forecast (this quarter)$1.41
Annual revenue (last year)$11.1B
Annual profit (last year)$480.0M
Net profit margin4.32%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Generic
Chief Executive Officer &
Director
Heather M. Bresch
President &
Director
Rajiv Malik
Corporate headquarters
Hatfield, Hertfordshire

Forecasts